Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — Merger or Acquisition (August 2020)
8 slides from Bico Group Ab Class B's merger presentation, Aug 17, 2020
Slide 1: CELLINK's transformational combination with Scienion creates a global leader in precision dispensing
CELLINK’s transformational combination with Scienion creates a global leader in precision dispensing 17 August 2020
Slide 2: Disclaimer
Introduction Disclaimer Important: You must read the following before continuing. The following applies to this document, any oral presentation of the information in this document by CELLINK AB (publ) (the "Company") or any person on behalf of the Company, and any question-and-answer session that fo
Slide 3: CELLINK's transformational combination with Scienion creates a global leader in precision dispensing
CELLINK’s transformational combination with Scienion creates a global leader in precision dispensing 1 Attractive Applications in multiple large, high-growth markets (e.g. single cell handling, liquid handling, array printing, genomics) TAM ~USD5bn5 markets Single cell-dispensing: Product feature an
Slide 4: Unique offering that addresses high-growth end markets
Unique offering that addresses high-growth end markets 100% owned subsidiary of Scienion Key products Key products sciFLEXARRAYER S3 sciFLEXARRAYER S12 sciFLEXARRAYER SX sciFLEXARRAYER S100 cellenONE X1 cellenONE F1.4 Entry level Medium-scale High-scale In-line high-throughput Phase contrast Multi-f
Slide 5: Scienion engages with blue-chip customers across Diagnostics, Biopharma and Life Science Research
Scienion engages with blue-chip customers across Diagnostics, Biopharma and Life Science Research Solutions for many types of products Academic and Research Institutions Biosensors and Point-of-Care Laboratory Systems Selected Institutions Instrument Systems Micro and Nano Arrays Single Cell Researc
Slide 6: Highly complementary technologies
Highly complementary technologies Opportunity Great opportunity in bioprinting combining CELLINK’s deep know-how and bioprinting technology with Single cell-dispensing Scienion’s dispensing technology Creating a dominant player in single-cell Leading technology Leading technology dispensing through
Slide 7: Exciting combined financial profile
Exciting combined financial profile Combined historical revenue development (EURm)1 Comments Cellink net sales based on 2Q LTM for the respective year (e.g. LTM Feb-2020 for 2019A) ▪ Combined growth profile of 57% CAGR over the past three years - Scienon’s strong revenue development of 34.0% CAGR 20
Slide 8: Key transaction features
Key transaction features ▪ Scienion is a global leader in next-gen precision dispensing Rationale ▪ Taking CELLINK “closer to the clinc” from R&D into High-Throughput production ▪ Creating a low volume dispensing powerhouse Synergies ▪ Expect to realize significant revenue and operational synergies